Esketamine is the active enantiomer of ketamine in terms of NMDA receptor antagonism and is more potent than racemic ketamine. [14] It is specifically used as a therapy for treatment-resistant depression (TRD) and for major depressive disorder (MDD) with …

There’s good news for people with severe treatment-resistant depression: Esketamine is a groundbreaking therapy that can provide relief from major depression within hours.

2 days ago · How Esketamine Nasal Spray Provides Relief A study by Johnson & Johnson, the company that makes Spravato, showed that 22.5% of people using esketamine nasal spray achieved remission from major ...

Jan 21, 2025 · The US Food and Drug Administration (FDA) approved esketamine (SPRAVATO) CIII nasal spray as the first monotherapy for adults with treatment-resistant depression (TRD), announced by Johnson & Johnson on January 21, 2025. 1. The approval of this supplemental New Drug Application (sNDA) was based on phase 4 randomized, double-blind, multicenter, …

Apr 22, 2024 · Easy-to-read patient leaflet for Esketamine. Includes indications, proper use, special instructions, precautions, and possible side effects. Skip to main content

1 day ago · Objective: Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The authors conducted a systematic review and meta-analysis of the available data on its efficacy against depression and suicidality as well as its side effects. Methods: MEDLINE was …

Spravato (esketamine) CIII nasal spray is approved by the U.S. Food and Drug Administration alone or in conjunction with an oral antidepressant for adults with MDD when they have inadequate response to at least two oral antidepressants (TRD) and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or ...

Sep 1, 2024 · Esketamine nasal spray is used together with an antidepressant taken by mouth, to treat patients with depression who have previously received at least 2 antidepressant treatments that did not work well (treatment-resistant depression).

Learn about SPRAVATO® (esketamine) CIII nasal spray, a prescription medicine for two indications. See full Prescribing & Safety Info, including BOXED WARNINGS.

Esketamine has been shown to be effective in decreasing the severity of short-term depressive symptoms, but questions about its medium- and long-term action, as well as its tolerability profile, remain to be elucidated as novel clinical studies explore its pharmaco-clinical properties.